Abstract 363P
Background
Metabolic syndrome (MetS) has been identified as a factor related to a worse prognosis in breast cancer. However, the association between adipocytokines and IL-18bp serum levels, MetS, and breast cancer is not demonstrated.
Methods
We prospectively evaluated 151 women with breast cancer eligible for neoadjuvant chemotherapy (NAC). We studied adipocytokines (resistin and leptin) and IL-18bp serum levels and their association with MetS, patients’ clinical and laboratory data, and clinical and pathological responses after NAC. Data analysis used the Fisher/Chi-Square and Mann-Whitney Tests (SPSS v20.0, p<0.05). Study approval number 5.332.237.
Results
134 subjects (95.7%) achieved clinical objective response (complete + partial). Among the 151 patients evaluated, 82 (54.3%) had MetS, with HDL-C <50 mg/dl being the most frequent criterion (n=72, 87,8%). Age>45 years, postmenopausal status, obesity, NAC dose reduction, and delay in performing surgery were more associated with the MetS group (p<0.01). MetS breast cancer patients with high resistin levels presented with positive lymph nodes (97%), >=88 cm waist circumference (94%), and invasive breast carcinoma of no special type (100%) versus the group with low levels of resistin (p<0.05). Additionally, high IL-18bp levels were associated with non-luminal A breast cancers (94%) versus 73% of patients with IL-18bp low levels (p<0.05). Leptin was elevated in patients with hyperglycemia and hypertriglyceridemia, while IL18-bp levels increased in subjects with HDL-C < 50md/dl (p<0.05). The higher frequency of objective response was associated with no need for dose reduction and low serum IL-18bp concentration (p<0.05).
Conclusions
High adipocytokines and IL-18bp serum levels are associated with lower objective response rates after neoadjuvant treatment in breast cancer patients with metabolic syndrome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
L. Mont'Alverne Arruda.
Funding
Funcap, CNPq, Ebserth, Capes.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
371P - Adherence to standardized and structured electronic symptom reporting (ePRO) via mobile app in HER2-positive breast cancer treated with HER2 biosimilar trastuzumab
Presenter: Andreas Trojan
Session: Poster session 03
372P - Prevalence of BRCA1 and BRCA2 mutation among Indian breast cancer patients: A multicentre cross-sectional study
Presenter: Shona Nag
Session: Poster session 03
374P - Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial
Presenter: Amrita Basu
Session: Poster session 03
375TiP - A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors
Presenter: Ludimila Cavalcante
Session: Poster session 03
388P - Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC)
Presenter: Junji Tsurutani
Session: Poster session 03
391P - Detrimental effect on overall survival of CDK4/6 inhibitor dose reduction if immortal time bias is considered
Presenter: Andreas Bjerrum
Session: Poster session 03
392P - The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer on first-line endocrine therapy with or without a CDK 4/6 inhibitor
Presenter: Senna Lammers
Session: Poster session 03